Natera executive chairman Matthew Rabinowitz sells $34.8m in stock By Investing.com

Matthew Rabinowitz, Executive Chairman of Natera, Inc. (), sold a total of 101,000 shares of the company’s common stock across multiple transactions on September 14 and 15, 2026. The sales amounted to a total value of $34,797,270. The shares were sold at weighted average prices ranging from $328.0942 to $351.245 per share. The timing of these sales comes as the stock trades at $345.34, near its 52-week high of $357.14, following a remarkable 97% gain over the past year. According to InvestingPro analysis, Natera currently appears overvalued relative to its Fair Value. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for NTRA and 1,400+ other US equities.

These transactions were conducted under pre-arranged Rule 10b5-1 trading plans. Specifically, the sales on September 14, 2026, involved 50,000 shares, while sales on September 15, 2026, involved 51,000 shares. Of the total, 99,000 shares were sold directly by Mr. Rabinowitz. An additional 2,000 shares were sold indirectly by his spouse, also under a separate Rule 10b5-1 trading plan adopted earlier.

Following these reported transactions, Mr. Rabinowitz directly beneficially owns 2,125,394 shares of Natera common stock.

In other recent news, Natera reported second-quarter revenue that significantly exceeded Wall Street expectations. The company achieved revenue of approximately $753 million, surpassing the forecasted $661.26 million. Management highlighted accelerated growth across its primary business areas, increased test volumes, improved margins, and several regulatory successes. Additionally, Natera raised its full-year revenue guidance, indicating strong business momentum. In related developments, Rothschild Redburn initiated coverage on Natera with a Buy rating, setting a price target of $385.00. The firm emphasized Natera’s leadership in minimal residual disease testing, particularly with its Signatera tumor-informed test. These recent developments reflect a period of robust performance and positive outlook for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.